TECLens was proud to be featured as a Showcase Innovator at the 2025 Innovators Pop-Up during the American Academy of Ophthalmology (AAO) Annual Meeting—marking the first-ever U.S. debut of its quantitative corneal cross-linking (qCXL™) technology.
During the event, ophthalmic leaders and industry innovators gathered to explore the next wave of vision correction breakthroughs. For many attendees, this was the first look at TECLens’ non-invasive quantitative corneal cross-linking technology (qCXL™) for vision correction. Our transformational CXLens® system uses patterned ultraviolet (UV) light to gently strengthen and reshape the cornea with continuous biomechanical control. qCXL™ is designed to be a comfortable, safe, and effective alternative to traditional refractive surgeries.
TECLens’ breakthrough technology aims to set a new standard in outcomes, accessibility, and patient experience — redefining vision correction with innovation that improves quality of life.
“Debuting qCXL™ to the U.S. ophthalmic community was a major milestone moment for our team,” said Tom Dunlap, CEO of TECLens. “This technology represents years of innovation focused on turning cross-linking from an art into a science—quantitative, controlled with real-time monitoring, and designed to truly reshape what’s possible for patients and providers.”
The Innovators Pop-Up was just the beginning. As TECLens advances into clinical studies, the company continues to pioneer the next generation of non-invasive, quantitative corneal reshaping—bringing the future of vision correction into focus.
Caution – Investigational Device. Limited by Federal (or United States) law to investigational use.